VIDEO: Mirikizumab safe, effective in Crohn’s disease treatment

ByKate Burba

Mirikizumab demonstrated sustained safety and efficacy at 52-weeks in patients with Crohn’s disease; these data support the ongoing VIVID phase 3 study, Bruce Sands, MD, Icahn School of Medicine told Healio Gastroenterology.

“Mirikizumab treatment demonstrated durable endoscopic and symptomatic efficacy after a year of treatment in patients with CD and the safety profile of mirikizumab treatment was consistent with what we know of this class with few discontinuations in the re-randomized maintenance group,” Sands said. “[These] phase 2 data support continued characterization of mirikizumab efficacy and safety.”

Published by:

Sources/Disclosures

Collapse

Source:

Sands B, et al. Abstract 132. Presented at: Digestive Disease Week; May 21-23 (virtual meeting).

Disclosures: Sands reports consulting for AbbVie, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Inotrem, Janssen, Johnson & Johnson, Kallyope, Pfizer, Protagonist Therapeutics, Surrozen and Takeda Pharmaceuticals; serving on an advisory committee or review panel for Abivax, Arena Pharmaceuticals, Immunic, Ironwood Pharmaceuticals, Lilly, Prometheus Biosciences IBD and Target RWE. Please see the study for all other authors’ relevant financial disclosures.

Digestive Disease Week

Read more

VIDEO: Mirikizumab safe, effective in Crohn’s disease treatment

Related Content